Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis

BMC Medical Genetics

Volumn 10, Issue , 2009, Pages 111-

  Chen, Suet N ^a,b   Cilingiroglu, Mehmet ^c   Todd, Josh ^d   Lombardi, Raffaella ^a   Willerson, James T ^a   Gotto Jr, Antonio M ^e   Ballantyne, Christie M ^b,f   Marian, AJ ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A5; APOLIPOPROTEIN C2; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; BODY MASS; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CIGARETTE SMOKING; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENDER; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION GENETICS; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 70749098299     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-10-111     Document Type: Article

References (37)

1. Lopez AD, Murray CC. The global burden of disease, 1990-2020. NatMed 1998, 4:1241-1243.
2. Genest JJ, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH, Silberman SR, Wilson PW, Salem DN, Schaefer EJ. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992, 85:2025-2033.
3. Ballantyne CM, Herd JA, Ferlic LL, Dunn JK, Farmer JA, Jones PH, Schein JR, Gotto AM. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 1999, 99:736-743.
4. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987, 317:1237-1245.
5. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001, 104:3046-3051. 10.1161/hc5001.100624, 11748098.
6. Goldbourt U, Yaari S, Medalie JH. Isolated Low HDL Cholesterol As a Risk Factor for Coronary Heart Disease Mortality: A 21-Year Follow-up of 8000 Men. Arteriosclerosis, Thrombosis, and Vascular Biology 1997, 17:107-113.
7. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA: The Journal of the American Medical Association 2001, 285:1585-1591. 10.1001/jama.285.12.1585, 11268266.
8. Bloomfield Rubins H, Davenport J, Babikian V, Brass LM, Collins D, Wexler L, Wagner S, Papademetriou V, Rutan G, Robins SJ. Reduction in Stroke With Gemfibrozil in Men With Coronary Heart Disease and Low HDL Cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 2001, 103:2828-2833.
9. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P. Simvastatin and Niacin, Antioxidant Vitamins, or the Combination for the Prevention of Coronary Disease. The New England Journal Of Medicine 2001, 345:1583-1592. 10.1056/NEJMoa011090, 11757504.
10. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD. Effects of Torcetrapib in Patients at High Risk for Coronary Events. The New England Journal Of Medicine 2007, 357:2109-2122. 10.1056/NEJMoa0706628, 17984165.
11. Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, Yu L, Brewer C, Collins JA, Molhuizen HO. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. NatGenet 1999, 22:336-345.
12. Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, Drobnik W, Barlage S, Buchler C, Porsch-Ozcurumez M. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. NatGenet 1999, 22:347-351.
13. Mathias RA, Roy-Gagnon MH, Justice CM, Papanicolaou GJ, Fan YT, Pugh EW, Wilson AF. Comparison of year-of-exam- and age-matched estimates of heritability in the Framingham Heart Study data. BMCGenet 2003, 4(Suppl 1):S36.
14. North KE, Howard BV, Welty TK, Best LG, Lee ET, Yeh JL, Fabsitz RR, Roman MJ, MacCluer JW. Genetic and environmental contributions to cardiovascular disease risk in American Indians: the strong heart family study. American Journal of Epidemiology 2003, 157:303-314. 10.1093/aje/kwf208, 12578801.
15. Perusse L, Rice T, Despres JP, Bergeron J, Province MA, Gagnon J, Leon AS, Rao DC, Skinner JS, Wilmore JH. Familial resemblance of plasma lipids, lipoproteins and postheparin lipoprotein and hepatic lipases in the HERITAGE Family Study. ArteriosclerThrombVascBiol 1997, 17:3263-3269.
16. Brenn T. Genetic and environmental effects on coronary heart disease risk factors in northern Norway. The cardiovascular disease study in Finnmark. AnnHumGenet 1994, 58(Pt 4):369-379.
17. Namboodiri KK, Kaplan EB, Heuch I, Elston RC, Green PP, Rao DC, Laskarzewski P, Glueck CJ, Rifkind BM. The Collaborative Lipid Research Clinics Family Study: biological and cultural determinants of familial resemblance for plasma lipids and lipoproteins. GenetEpidemiol 1985, 2:227-254.
18. Rao DC, Laskarzewski PM, Morrison JA, Khoury P, Kelly K, Wette R, Russell J, Glueck CJ. The Cincinnati Lipid Research Clinic family study: cultural and biological determinants of lipids and lipoprotein concentrations. AmJHumGenet 1982, 34:888-903.
19. Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, Rieder MJ, Cooper GM, Roos C, Voight BF, Havulinna AS. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008, 40:189-197. 2682493, 18193044, 10.1038/ng.75.
20. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC, Timpson NJ, Najjar SS, Stringham HM. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 2008, 40:161-169. 10.1038/ng.76, 18193043.
21. Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ, Jones PH, West MS, Gould KL, Gotto AM. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). AmJCardiol 1997, 80:278-286.
22. Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabezon E, Champagne E, Pineau T, Georgeaud V, Walker JE, Terce F. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003, 421:75-79. 10.1038/nature01250, 12511957.
23. Rodriguez S, Gaunt TR, Day IN. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 2009, 169:505-514. 2640163, 19126586, 10.1093/aje/kwn359.
24. Storey JD, Tibshirani R. Statistical significance for genomewide studies. ProcNatlAcadSci USA 2003, 100:9440-9445.
25. de Grooth GJ, Zerba KE, Huang SP, Tsuchihashi Z, Kirchgessner T, Belder R, Vishnupad P, Hu B, Klerkx AHEM, Zwinderman AH. The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: A prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy. Journal of the American College of Cardiology 2004, 43:854-857. 10.1016/j.jacc.2003.08.056, 14998629.
26. Corbex M, Poirier O, Fumeron F, Betoulle D, Evans A, Ruidavets JB, Arveiler D, Luc G, Tiret L, Cambien F. Extensive association analysis between the CETP gene and coronary heart disease phenotypes reveals several putative functional polymorphisms and gene-environment interaction. GenetEpidemiol 2000, 19:64-80.
27. Yamada Y, Matsuo H, Warita S, Watanabe S, Kato K, Oguri M, Yokoi K, Metoki N, Yoshida H, Satoh K. Prediction of genetic risk for dyslipidemia. Genomics 2007, 90:551-558. 10.1016/j.ygeno.2007.08.001, 17919884.
28. Carr MC, Ayyobi AF, Murdoch SJ, Deeb SS, Brunzell JD. Contribution of hepatic lipase, lipoprotein lipase, and cholesteryl ester transfer protein to LDL and HDL heterogeneity in healthy women. ArteriosclerThrombVascBiol 2002, 22:667-673.
29. Couture P, Otvos JD, Cupples LA, Lahoz C, Wilson PW, Schaefer EJ, Ordovas JM. Association of the C-514T polymorphism in the hepatic lipase gene with variations in lipoprotein subclass profiles: The Framingham Offspring Study. ArteriosclerThrombVascBiol 2000, 20:815-822.
30. Deeb SS, Peng R. The C-514T polymorphism in the human hepatic lipase gene promoter diminishes its activity. J Lipid Res 2000, 41:155-158.
31. Dugi KA, Brandauer K, Schmidt N, Nau B, Schneider JG, Mentz S, Keiper T, Schaefer JR, Meissner C, Kather H. Low hepatic lipase activity is a novel risk factor for coronary artery disease. Circulation 2001, 104:3057-3062. 10.1161/hc5001.100795, 11748100.
32. Wang J, Ban MR, Kennedy BA, Anand S, Yusuf S, Huff MW, Pollex RL, Hegele RA. APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia. Nat Clin Pract Cardiovasc Med 2008, 5:730-737. 10.1038/ncpcardio1326, 18779834.
33. Connelly PW, Maguire GF, Hofmann T, Little JA. Structure of apolipoprotein C-IIToronto, a nonfunctional human apolipoprotein. Proc Natl Acad Sci USA 1987, 84:270-273. 304185, 3467353, 10.1073/pnas.84.1.270.
34. Kathiresan S, Melander O, Anevski D, Guiducci C, Burtt NP, Roos C, Hirschhorn JN, Berglund G, Hedblad B, Groop L. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 2008, 358:1240-1249. 10.1056/NEJMoa0706728, 18354102.
35. Boekholdt SM, Sacks FM, Jukema JW, Shepherd J, Freeman DJ, McMahon AD, Cambien F, Nicaud V, de Grooth GJ, Talmud PJ. Cholesteryl Ester Transfer Protein TaqIB Variant, High-Density Lipoprotein Cholesterol Levels, Cardiovascular Risk, and Efficacy of Pravastatin Treatment: Individual Patient Meta-Analysis of 13 677 Subjects. Circulation 2005, 111:278-287. 10.1161/01.CIR.0000153341.46271.40, 15655129.
36. Goring HHH, Curran JE, Johnson MP, Dyer TD, Charlesworth J, Cole SA, Jowett JBM, Abraham LJ, Rainwater DL, Comuzzie AG. Discovery of expression QTLs using large-scale transcriptional profiling in human lymphocytes. Nat Genet 2007, 39:1208-1216. 10.1038/ng2119, 17873875.
37. Li X, Zhang S, Blander G, Tse JG, Krieger M, Guarente L. SIRT1 Deacetylates and Positively Regulates the Nuclear Receptor LXR. Molecular Cell 2007, 28:91-106. 10.1016/j.molcel.2007.07.032, 17936707.